You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
Shift work disorder is among the sleep/wake disorders that are most commonly undiagnosed and undertreated. Approximately 22 million Americans perform some type of nonstandard shift work and are at risk for this disorder. Characterized by excessive sleepiness and/or insomnia, shift work disorder is associated with depression, GI disorders, heart disease, stroke, and cancer. This Webcast is based on one of a series of dinner meetings that were held across the country to educate primary care and other healthcare professionals about the role of circadian rhythms in sleep/wake function and strategies for recognizing, diagnosing, and managing patients with shift work disorder.
Click here to see related programs in this series.
Click here for the Sleep/Wake Disorders Video Q&A.
Upon completion of this educational activity, participants should be better able to:
ACCREDITOR DISCLOSURE OF CONFLICTS OF INTEREST POLICY
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity, or who refuses to provide all their conflict-of-interest information, will not be permitted to present.
Thomas Roth, PhD, receives grant/research support from Merck & Co., Inc., and serves as a consultant for Abbott Laboratories, Cephalon, Inc., Eisai Inc., Intec, Merck & Co., Inc., Ocera Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., sanofi-aventis, Shire, Somaxon Pharmaceuticals, Somnus Therapeutics, Takeda Pharmaceuticals North America, and TransOral Pharmaceuticals, Inc. Dr. Roth is on the speakers’ bureau for Cephalon, Inc.
Phyllis C. Zee, MD, PhD, serves as a consultant for Takeda Pharmaceuticals North America, Cephalon, Inc., Merck & Co., Inc., sanofi-aventis, and Philips Respironics.
Paul P. Doghramji, MD, FAAFP, serves as a consultant for Pfizer Inc. Dr. Doghramji is on the speakers’ bureaus for Cephalon, Inc., AstraZeneca, Pfizer Inc., and Takeda Pharmaceuticals North America.
Richard K. Bogan, MD, FCCP, FAASM, receives grant/research support for Actellion, Alza, Arena, Boehringer Ingelheim, Cephalon, Inc., GlaxoSmithKline, Jazz, Vanda, Neurogen, Evotec, Merck & Co., Inc., Lilly, Pfizer Inc., Novartis, sanofi-aventis, Schwarz, Sepracor, and Xenoport. Dr. Bogan is a consultant for GlaxoSmithKline, Jazz, ApniCure, Addrenex, UCB, and is on the speakers’ bureaus for sanofi-aventis, Sepracor, Cephalon Inc., and Jazz. Dr. Bogan is also a shareholder and employee of SleepMed, Inc.
David W. Appel, MD, has nothing to disclose.
HAYMARKET MEDICAL EDUCATION STAFF DISCLOSURES
Mary Jo Krey, Eileen McCaffrey, Ana Maria Albino, and Lynne Callea have no financial relationship with the grantor and/or any commercial interest.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva University, and HME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva University, and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Sponsored by the Albert Einstein College of Medicine of Yeshiva University
Supported by an educational grant from Cephalon, Inc., in collaboration with SleepMed, Inc.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Haymarket Medical Education LP. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Each course participant should only claim credits commensurate with the extent of their participation in the activity. This CME activity was planned and produced in accordance with the ACCME Essentials.
To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.